Scientists use the Toronto-based firm’s AI tools to improve experiments in the drug-discovery and -development process. The company had previously raised $60 million from Canadian investors including Inovia Capital, Northleaf Capital Partners, Golden Ventures and Real Ventures, as well as Google’s Gradient Ventures and Cambridge, Mass.-based health-care financier F-Prime Capital. (The Logic)
Talking point: BenchSci will use the money to expand its platform to more areas of pharmaceutical R&D. The firm has 210 staff after doubling its workforce last year, and plans to add as many again in 2022. Health-care applications of AI are having a financing moment, “attracting the highest level of VC funding of any AI subsegment,” driven by drug discovery, PitchBook said in a May 2021 report, predicting pharmaceutical giants will begin to acquire startups in the space once algorithm-identified treatments hit the market. In Canada, Vancouver’s AbCellera raised US$110 million in venture funding before a US$555.5-million December 2020 IPO, while SoftBank led a US$180-million for Toronto’s Deep Genomics in July 2021.